ClinicalTrials.gg
CompletedNCT01238861Updated Nov 17, 2016Results posted

Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma

A Phase 2 interventional study of Benralizumab 2 mg and Benralizumab 20 mg in Asthma, sponsored by MedImmune LLC. Completed at 79 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-11-17.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
964
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
4th of 39
964 · median 128
Started
2010
the only one that year
Phase 2
7 of 39
none open now
Registered
5th of 39
by date
Lead sponsor
5 of 39
MedImmune LLC

Among the 39 studies testing benralizumab in Asthma, this one is the 4th largest by enrollment, is the only one that started in 2010, is one of 7 in phase 2, and was the 5th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the effect of multiple-dose subcutaneous administrations of MEDI-563 on adults with uncontrolled asthma.

Read the detailed description

This is a Phase 2b, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of multiple-dose (7 doses) subcutaneous administration of benralizumab (MEDI-563) in adult subjects with uncontrolled asthma.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Benralizumab
  • MEDI-563
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 through 75 years at the time of screening
  • Adequate from screening through end of trial
  • Weight of more than (>) 45 kilogram (kg) but less than or equal to (\<=) 150 kg (>100 pound [lb] but \<=330 lb)
  • History of physician-diagnosed asthma for at least 12 months prior to screening
  • Physician prescribed daily use of medium-dose or high-dose inhaled (s) (ICS) plus long-acting beta 2 agonist (LABA) for at least 12 months prior to screening
  • Willingness to switch to an ICS/LABA combination product
  • Dose of other asthma controller medications must be stable for at least 30 days prior to screening
  • At least 2 documented asthma exacerbations in the 12 months prior to screening that required use of a systemic corticosteroid burst
  • For subjects 65 years of age or older, a chest x-ray (CXR) or chest computed tomography (CT) that is normal for an asthmatic population
  • Ability and willingness to complete the study to Week 66, and if needed to Week 92.

Exclusion criteria

Exclusion Criteria:

  • Known history of allergy or reaction to any component of the product formulation
  • History of anaphylaxis to any biologic therapy
  • Unexplained diarrhea within 30 days prior to screening or diagnosis of helminth parasitic infestation within 6 months prior to screening
  • Use of medication within 3 months prior to screening. Chronic oral prednisone or equivalent up to 10 milligram (mg) daily or 20 mg every other day for asthma is allowed
  • Oral burst or short-acting systemic corticosteroid within 30 days prior to screening or during the screening/run-in period
  • Acute upper or lower respiratory infections requiring antibiotics or antiviral medications within 30 days prior to the screening or during the screening/run-in period
  • Receipt of immunoglobulin or blood products within 30 days prior to screening
  • Receipt of any marketed or investigational biologic within 4 months or 5 half-lives prior to screening, whichever is longer
  • Receipt of any investigational nonbiologic within 30 days or 5 half-lives prior to screening, whichever is longer
  • Previously received MEDI-563
  • Any abnormal findings in physical examination
  • Past history of clinically significant cardiac disease or any (ECG) abnormality
  • Breastfeeding or lactating women
  • History of alcohol or drug abuse within 12 months prior to screening
  • History of any known primary immunodeficiency disorder
  • Positive medical history for or C. Subjects with a history of hepatitis B vaccination without history of hepatitis B are allowed to enrol
  • A positive (HIV) test or subject taking antiretroviral medications
  • History of cigarette smoking more than or equal to (>=) 10 pack-years or smoking within 12 months prior to screening.
  • Known exposure to inhaled occupational agents or fumes with an established diagnosis of occupational asthma
  • History of cancer, except for basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy >=12 months prior to screening or other treated with apparent success with curative therapy >=5 years prior to screening
  • Stable dose of allergy vaccination regimen for less than 30 days prior to screening
  • Subjects unable to demonstrate acceptable inhaler and peak flow meter techniques.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
964 participants (actual)

Study arms

  • Placebo comparator
    Eosinophilic phenotype (EOS+) Placebo

    EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo injections subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Other: Placebo

  • Experimental
    EOS+ Benralizumab (2 mg)

    EOS+ participants received single benralizumab 2 milligram (mg) injection subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Biological: Benralizumab 2 mg

  • Experimental
    EOS+ Benralizumab (20 mg)

    EOS+ participants received single benralizumab 20 mg injection subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Biological: Benralizumab 20 mg

  • Experimental
    EOS+ Benralizumab (100 mg)

    EOS+ participants received benralizumab 50 mg as two injections subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Biological: Benralizumab 100 mg

  • Placebo comparator
    Non-eosinophil phenotype (EOS-) Placebo

    EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Other: Placebo

  • Experimental
    EOS- Benralizumab (100 mg)

    EOS- participants received benralizumab 50 mg as two injections subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Biological: Benralizumab 100 mg

Interventions

  • EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.

    Also known as: MEDI-563

  • EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.

    Also known as: MEDI-563

  • EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.

    Also known as: MEDI-563

  • OtherPlacebo

    EOS+ and EOS- participants received two placebo injections subcutaneously.

06

What researchers measure

Primary outcomes

  1. Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants

    The annual asthma exacerbation rate (AER) was calculated as the total number of observed exacerbations in each group up to week 52, divided by total duration of person-year follow-up in each group. An asthma exacerbation is defined as a progressive increase of asthma symptoms (cough, wheeze, chest tightness, and/or shortness of breath) that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 days as prescribed or administered by the investigator or healthcare provider; or 2) participant initiation of systemic corticosteroids (tablets, suspension or injection) for a duration of at least 3 days as outlined in the Asthma Action Plan provided to the participant by the investigator on Day 1.

    Time frame: Week 1 up to Week 52

Secondary outcomes

  1. Dose Response in EOS+ Participants

    Time frame: Baseline up to Week 66

  2. Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ss)

    Time frame: Pre-dose (0 hour), Post-dose on Day 1, 6, Week 4, 16, 24, 32, 40, and 52

  3. Dose-Normalized Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ssD)

    Time frame: Pre-dose (0 hour), Post-dose on Day 1, 6, Week 4, 16, 24, 32, 40, and 52

  4. Percentage of Participants With Anti-Drug Antibodies (ADA) to Benralizumab in Eosinophilic Phenotype (EOS+) Participants

    Immunogenicity assessment included determination of anti-drug (benralizumab) antibodies in serum samples. ADA positive was defined as a titer \>=50 at any point in the study. It was observed at baseline and any visit during the study.

    Time frame: Baseline up to Week 92

  5. Change From Baseline in Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 52

    Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score was the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Data collected on Day 1 prior to dosing was considered as baseline. Results were reported for overall ACQ score. ACQ-6 score was summarized together for all participants.

    Time frame: Baseline up to Week 52

  6. Change From Baseline in Mean Total Nasal Symptoms Score (TNSS) at Week 52

    Total Nasal Symptoms Score (TNSS) is a 3-item questionnaire, the sum of nasal symptoms, namely, nasal obstruction (rhinorrhea), nasal congestion, and nasal itching/sneezing. Each symptom was rated on a scale from 0-3, with 0 representing no symptoms, 1 mild, 2 moderate, and 3 severe symptoms. TNSS score was a summation of the 3 individual nasal symptom. TNSS score could range from 0 to 9 where higher score indicates worsening. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

    Time frame: Baseline up to Week 52

  7. Change From Baseline in Mean Asthma Symptom Diary Score at Week 51-52

    Asthma Symptom Diary included 7 questions about the participant symptom and the overall impact of treatment on the disease during the study period. Mean scores of the 7 questions were calculated to identify asthma symptom-free days. Asthma Symptom Diary Scores were analyzed on a bi-weekly basis and compared to baseline scores. Overall symptom score=(daytime frequency score + daytime severity score + nighttime severity score)/3, where total score ranges from 0 to 9. Higher score represents worsening. Mean asthma symptom diary score were summarized together for all participants. Mean asthma symptom diary score were summarized together for all participants. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

    Time frame: Baseline up to Week 51-52

  8. Change From Baseline in Rescue Medication Use at Week 51-52

    Participants were provided inhalers of the same dose (medium- or high-dose) inhaled corticosteroid (ICS) plus long-acting beta antagonist (LABA) combination product as baseline prophylactic medication and continued with same dose throughout the study. Rescue medications such as short-term beta2 agonists were used as first-line treatment for worsening asthma symptoms. Investigator prescribed additional short term asthma controller medications included additional ICS, theophylline, inhaled cromones or antimuscarinics; if asthma symptoms remained mild but not resolved. If asthma symptoms worsened, participants received an oral corticosteroid burst. All rescue medications use with prophylactic medication (+ prophylactic) and without prophylactic medication (- prophylactic) was recorded in asthma symptom dairy by participant. Rescue medication use was analyzed on a bi-weekly basis and compared to baseline scores.

    Time frame: Baseline up to Week 51-52

  9. Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52

    FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

    Time frame: Baseline and Week 52

  10. Change From Baseline in Mean Forced Vital Capacity (FVC) at Week 52

    Forced Vital Capacity (FVC) was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible.

    Time frame: Baseline and Week 52

  11. Change From Baseline in Peak Expiratory Flow (PEF) at Week 52

    The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed while sitting or standing prior to using any medication (if needed) for asthma. Home PEF was determined separately for morning and evening, and were averaged for each participant. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

    Time frame: Baseline and Week 52

  12. Change From Baseline in Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ[S]) Score at Week 52

    AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment). The AQLQ(S) responses were categorized as improvement (defined as change from baseline \>=0.5), no change (defined as change from baseline \>= -0.5 to less than \[\<\] 0.5), and worse (defined as change from baseline \< -0.5). Data was summarized by each treatment group.

    Time frame: Baseline and Week 52

  13. Change From Baseline in European Quality of Life - 5 Dimensions (EQ-5D) Health State Evaluation at Week 52

    The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The health state valuation was the summary score of mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a 3 category scale (no problem, moderate problem, severe problems). Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

    Time frame: Baseline and Week 52

  14. Change From Baseline in EQ-5D Visual Analog Scale (VAS) at Week 52

    The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The EQ-5D VAS was measured from 0 (worst imaginable health state) to 100 (best imaginable health state). Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

    Time frame: Baseline and Week 52

  15. Change From Baseline in Percentage of Nocturnal Awakening-Free Nights at Week 51-52

    Percentage of nocturnal awakening-free nights were analyzed on a bi-weekly basis and compared to baseline scores. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

    Time frame: Baseline up to Week 51-52

  16. Change From Baseline in Mean Fraction Exhaled Nitric Oxide (FeNO) at Week 52

    Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

    Time frame: Baseline up to Week 52

07

Results

Posted Nov 17, 2016

Participant flow

Participant flow — Overall Study
MilestoneEosinophilic Phenotype (EOS+) PlaceboEOS+ Benralizumab, 2 mgEOS+ Benralizumab, 20 mgEOS+ Benralizumab, 100 mgNon-eosinophil Phenotype (EOS-) PlaceboEOS- Benralizumab, 100 mg
Started80818182142140
Completed69737069129125
Not completed11811131315
Withdrew: Lost to follow-up423112
Withdrew: Unplanned surgery100000
Withdrew: Did not meet entry acq-6 criteria001011
Withdrew: Incorrect enrollment/randomization001010
Withdrew: Subject traveled to argentina by 1 year001000
Withdrew: Subject moved out of state/area001100
Withdrew: Strongyloides stercoralis antibodies +000100
Withdrew: Personal problems000100
Withdrew: Unable to continue visits000101
Withdrew: Serious adverse event000001
Withdrew: Lack of compliance000001
Withdrew: Adverse event010000
Withdrew: Withdrawal by subject6548109

Outcome measures

PrimaryAnnual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants

The annual asthma exacerbation rate (AER) was calculated as the total number of observed exacerbations in each group up to week 52, divided by total duration of person-year follow-up in each group. An asthma exacerbation is defined as a progressive increase of asthma symptoms (cough, wheeze, chest tightness, and/or shortness of breath) that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 days as prescribed or administered by the investigator or healthcare provider; or 2) participant initiation of systemic corticosteroids (tablets, suspension or injection) for a duration of at least 3 days as outlined in the Asthma Action Plan provided to the participant by the investigator on Day 1.

Time frame:
Week 1 up to Week 52
Reported as:
Number · AER events/person-year
Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants
AER events/person-yearEosinophilic Phenotype (EOS+) PlaceboEOS+ Benralizumab, 2 mgEOS+ Benralizumab, 20 mgEOS+ Benralizumab, 100 mg
Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants0.570.650.370.34
Statistical analysis
  • Eosinophilic Phenotype (EOS+) Placebo vs EOS+ Benralizumab, 2 mg · Poisson Regression Method · p = 0.781 · Rate ratio: 1.09 · 80% CI 0.74 to 1.59The p-value was calculated by Poisson regression with over-dispersion adjustment factor. The correction for potential over dispersion was made by Pearson chi-square.
  • Eosinophilic Phenotype (EOS+) Placebo vs EOS+ Benralizumab, 20 mg · Poisson Regression Method · p = 0.173 · Rate ratio: 0.64 · 80% CI 0.42 to 0.97The p-value was calculated by Poisson regression with over-dispersion adjustment factor. The correction for potential over dispersion was made by Pearson chi-square.
  • Eosinophilic Phenotype (EOS+) Placebo vs EOS+ Benralizumab, 100 mg · Poisson Regression Method · p = 0.096 · Rate ratio: 0.59 · 80% CI 0.40 to 0.89The p-value was calculated by Poisson regression with over-dispersion adjustment factor. The correction for potential over dispersion was made by Pearson chi-square.
SecondaryDose Response in EOS+ Participants
Time frame:
Baseline up to Week 66

No measurements were reported for this outcome.

SecondaryMinimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ss)
Time frame:
Pre-dose (0 hour), Post-dose on Day 1, 6, Week 4, 16, 24, 32, 40, and 52
Reported as:
Mean · microgram per milliliter
Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ss)
microgram per milliliterEOS+ Benralizumab, 2 mgEOS+ Benralizumab, 20 mgBenralizumab, 100 mg
Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ss)34.7 ± 131182 ± 180869 ± 665
SecondaryDose-Normalized Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ssD)
Time frame:
Pre-dose (0 hour), Post-dose on Day 1, 6, Week 4, 16, 24, 32, 40, and 52
Reported as:
Mean · microgram per milliliter
Dose-Normalized Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ssD)
microgram per milliliterEOS+ Benralizumab, 2 mgEOS+ Benralizumab, 20 mgBenralizumab, 100 mg
Dose-Normalized Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ssD)17.3 ± 65.39.10 ± 9.028.69 ± 6.65
SecondaryPercentage of Participants With Anti-Drug Antibodies (ADA) to Benralizumab in Eosinophilic Phenotype (EOS+) Participants

Immunogenicity assessment included determination of anti-drug (benralizumab) antibodies in serum samples. ADA positive was defined as a titer \>=50 at any point in the study. It was observed at baseline and any visit during the study.

Time frame:
Baseline up to Week 92
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-Drug Antibodies (ADA) to Benralizumab in Eosinophilic Phenotype (EOS+) Participants
percentage of participantsEOS+ PlaceboEOS+ Benralizumab, 2 mgEOS+ Benralizumab, 20 mgEOS+ Benralizumab, 100 mg
Percentage of Participants With Anti-Drug Antibodies (ADA) to Benralizumab in Eosinophilic Phenotype (EOS+) Participants3.842.030.925.6
SecondaryChange From Baseline in Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 52

Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score was the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Data collected on Day 1 prior to dosing was considered as baseline. Results were reported for overall ACQ score. ACQ-6 score was summarized together for all participants.

Time frame:
Baseline up to Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 52
units on a scaleEOS+ PlaceboEOS+ Benralizumab, 2 mgEOS+ Benralizumab, 20 mgEOS+ Benralizumab, 100 mgEOS- PlaceboEOS- Benralizumab, 100 mg
Baseline (n=80,80,80,82,142,140)2.7479 ± 0.97622.6479 ± 0.99082.4750 ± 0.91062.5346 ± 0.97282.4742 ± 0.84082.6381 ± 0.8330
Change at Week 52 (n=34,42,40,39,64,73)-0.8922 ± 1.1969-1.1032 ± 1.1207-1.2500 ± 1.2247-1.1239 ± 1.2852-0.8418 ± 1.1343-1.1295 ± 1.1301
Statistical analysis
  • EOS+ Placebo vs EOS+ Benralizumab, 2 mg · ANCOVA · p = 0.125P-value was calculated by analysis of covariance (ANCOVA) with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • EOS+ Placebo vs EOS+ Benralizumab, 20 mg · ANCOVA · p = 0.074P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • EOS+ Placebo vs EOS+ Benralizumab, 100 mg · ANCOVA · p = 0.057P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • EOS- Placebo vs EOS- Benralizumab, 100 mg · ANCOVA · p = 0.010P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
SecondaryChange From Baseline in Mean Total Nasal Symptoms Score (TNSS) at Week 52

Total Nasal Symptoms Score (TNSS) is a 3-item questionnaire, the sum of nasal symptoms, namely, nasal obstruction (rhinorrhea), nasal congestion, and nasal itching/sneezing. Each symptom was rated on a scale from 0-3, with 0 representing no symptoms, 1 mild, 2 moderate, and 3 severe symptoms. TNSS score was a summation of the 3 individual nasal symptom. TNSS score could range from 0 to 9 where higher score indicates worsening. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

Time frame:
Baseline up to Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Mean Total Nasal Symptoms Score (TNSS) at Week 52
units on a scalePlaceboEOS+ Benralizumab, 2 mgEOS+ Benralizumab, 20 mgBenralizumab (100 mg)
Baseline (n=71,27,25,81)4.3 ± 2.04.8 ± 2.05.3 ± 1.84.4 ± 2.1
Change at Week 52 (n=89,39,39,106)-0.4 ± 2.90-0.8 ± 2.01-1.0 ± 2.96-0.8 ± 2.24
SecondaryChange From Baseline in Mean Asthma Symptom Diary Score at Week 51-52

Asthma Symptom Diary included 7 questions about the participant symptom and the overall impact of treatment on the disease during the study period. Mean scores of the 7 questions were calculated to identify asthma symptom-free days. Asthma Symptom Diary Scores were analyzed on a bi-weekly basis and compared to baseline scores. Overall symptom score=(daytime frequency score + daytime severity score + nighttime severity score)/3, where total score ranges from 0 to 9. Higher score represents worsening. Mean asthma symptom diary score were summarized together for all participants. Mean asthma symptom diary score were summarized together for all participants. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

Time frame:
Baseline up to Week 51-52
Reported as:
Mean · units on a scale
Change From Baseline in Mean Asthma Symptom Diary Score at Week 51-52
units on a scalePlaceboEOS+ Benralizumab, 2 mgEOS+ Benralizumab, 20 mgBenralizumab (100 mg)
Baseline (n=204,72,74,210)1.58 ± 0.601.65 ± 0.651.60 ± 0.611.60 ± 0.62
Change at Week 51-52 (n=111,36,39,111)-0.37 ± 0.61-0.56 ± 0.76-0.56 ± 0.69-0.53 ± 0.67
Statistical analysis
  • Placebo vs EOS+ Benralizumab, 2 mg · ANCOVA · p = 0.131 · Mean difference (final values): -0.182 · 80% CI -0.336 to -0.028P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • Placebo vs EOS+ Benralizumab, 20 mg · ANCOVA · p = 0.126 · Mean difference (final values): -0.173 · 80% CI -0.317 to -0.028P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • Placebo vs Benralizumab (100 mg) · ANCOVA · p = 0.097 · Mean difference (final values): -0.140 · 80% CI -0.247 to -0.032P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
SecondaryChange From Baseline in Rescue Medication Use at Week 51-52

Participants were provided inhalers of the same dose (medium- or high-dose) inhaled corticosteroid (ICS) plus long-acting beta antagonist (LABA) combination product as baseline prophylactic medication and continued with same dose throughout the study. Rescue medications such as short-term beta2 agonists were used as first-line treatment for worsening asthma symptoms. Investigator prescribed additional short term asthma controller medications included additional ICS, theophylline, inhaled cromones or antimuscarinics; if asthma symptoms remained mild but not resolved. If asthma symptoms worsened, participants received an oral corticosteroid burst. All rescue medications use with prophylactic medication (+ prophylactic) and without prophylactic medication (- prophylactic) was recorded in asthma symptom dairy by participant. Rescue medication use was analyzed on a bi-weekly basis and compared to baseline scores.

Time frame:
Baseline up to Week 51-52
Reported as:
Mean · rescue medication per 2 weeks
Change From Baseline in Rescue Medication Use at Week 51-52
rescue medication per 2 weeksPlaceboEOS+ Benralizumab, 2 mgEOS+ Benralizumab, 20 mgBenralizumab (100 mg)
Baseline without prophylactic (n=204,72,74,210)3.09 ± 2.553.57 ± 3.673.82 ± 4.343.16 ± 2.82
Baseline with prophylactic (n=204,72,74,210)4.07 ± 3.344.71 ± 5.565.24 ± 6.404.22 ± 3.90
Change Week 51-52 -prophylactic(n=111,36,39,111)-1.2540 ± 2.4571-1.4116 ± 2.8722-1.8804 ± 5.3129-1.1589 ± 2.0086
Change Week 51-52 +prophylactic(n=111,36,39,111)-1.6855 ± 3.2875-1.6810 ± 4.2247-2.5118 ± 7.6814-1.4693 ± 2.5603
Statistical analysis
  • Placebo vs EOS+ Benralizumab, 2 mg · ANCOVA · p = 0.642 · Mean difference (final values): -0.174 · 80% CI -0.654 to 0.306P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • Placebo vs EOS+ Benralizumab, 20 mg · ANCOVA · p = 0.824 · Mean difference (final values): 0.111 · 80% CI -0.533 to 0.756P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • Placebo vs Benralizumab (100 mg) · ANCOVA · p = 0.910 · Mean difference (final values): 0.029 · 80% CI -0.297 to 0.355P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • Placebo vs EOS+ Benralizumab, 2 mg · ANCOVA · p = 0.992 · Mean difference (final values): -0.004 · 80% CI -0.602 to 0.593P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • Placebo vs EOS+ Benralizumab, 20 mg · ANCOVA · p = 0.624 · Mean difference (final values): 0.337 · 80% CI -0.548 to 1.222P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • Placebo vs Benralizumab (100 mg) · ANCOVA · p = 0.645 · Mean difference (final values): 0.150 · 80% CI -0.267 to 0.567P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
SecondaryChange From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52

FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

Time frame:
Baseline and Week 52
Reported as:
Mean · liters
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52
litersPlaceboEOS+ Benralizumab, 2 mgEOS+ Benralizumab, 20 mgBenralizumab (100 mg)
Baseline (n=215,80,81,218)2.033 ± 0.6691.978 ± 0.7012.080 ± 0.7512.012 ± 0.672
Change at Week 52 (n=150,51,58,160)0.0098 ± 0.36150.1631 ± 0.46910.1847 ± 0.52340.0998 ± 0.3541
Statistical analysis
  • Placebo vs EOS+ Benralizumab, 2 mg · ANCOVA · p = 0.014 · Mean difference (final values): 0.157 · 80% CI 0.076 to 0.237P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • Placebo vs EOS+ Benralizumab, 20 mg · ANCOVA · p = 0.004 · Mean difference (final values): 0.184 · 80% CI 0.102 to 0.266P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • Placebo vs Benralizumab (100 mg) · ANCOVA · p = 0.026 · Mean difference (final values): 0.091 · 80% CI 0.039 to 0.143P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
SecondaryChange From Baseline in Mean Forced Vital Capacity (FVC) at Week 52

Forced Vital Capacity (FVC) was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible.

Time frame:
Baseline and Week 52
Reported as:
Mean · liters
Change From Baseline in Mean Forced Vital Capacity (FVC) at Week 52
litersEOS+ PlaceboEOS+ Benralizumab, 2 mgEOS+ Benralizumab, 20 mgEOS+ Benralizumab, 100 mgEOS- PlaceboEOS- Benralizumab, 100 mg
Baseline (n=80,80,81,82,135,136)3.282 ± 1.0303.069 ± 0.9573.285 ± 1.0283.110 ± 0.8513.043 ± 0.8643.126 ± 0.981
Change at Week 52 (n=51,51,58,59,99,101)0.029 ± 0.5140.129 ± 0.5650.190 ± 0.5860.166 ± 0.445-0.030 ± 0.4260.056 ± 0.371
Statistical analysis
  • EOS+ Placebo vs EOS+ Benralizumab, 2 mg · ANCOVA · p = 0.384P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • EOS+ Placebo vs EOS+ Benralizumab, 20 mg · ANCOVA · p = 0.092P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • EOS+ Placebo vs EOS+ Benralizumab, 100 mg · ANCOVA · p = 0.134P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • EOS- Placebo vs EOS- Benralizumab, 100 mg · ANCOVA · p = 0.129P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
SecondaryChange From Baseline in Peak Expiratory Flow (PEF) at Week 52

The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed while sitting or standing prior to using any medication (if needed) for asthma. Home PEF was determined separately for morning and evening, and were averaged for each participant. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

Time frame:
Baseline and Week 52
Reported as:
Mean · liters per minute
Change From Baseline in Peak Expiratory Flow (PEF) at Week 52
liters per minutePlaceboEOS+ Benralizumab, 2 mgEOS+ Benralizumab, 20 mgBenralizumab (100 mg)
Baseline (n=215,80,81,218)319.3 ± 104.7325.5 ± 101.6323.1 ± 100.8323.8 ± 101.7
Change at Week 52 (n=150,51,58,160)13.0 ± 64.629.0 ± 64.145.9 ± 95.526.6 ± 66.3
SecondaryChange From Baseline in Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ[S]) Score at Week 52

AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment). The AQLQ(S) responses were categorized as improvement (defined as change from baseline \>=0.5), no change (defined as change from baseline \>= -0.5 to less than \[\<\] 0.5), and worse (defined as change from baseline \< -0.5). Data was summarized by each treatment group.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ[S]) Score at Week 52
units on a scalePlaceboEOS+ Benralizumab, 2 mgEOS+ Benralizumab, 20 mgBenralizumab (100 mg)
Baseline (n=214,78,80,217)3.72 ± 1.043.72 ± 1.173.79 ± 1.063.72 ± 1.01
Change at Week 52 (n=88,39,38,105)0.9634 ± 1.33421.2612 ± 1.20821.4474 ± 1.42621.1223 ± 1.2636
Statistical analysis
  • Placebo vs EOS+ Benralizumab, 2 mg · ANCOVA · p = 0.069 · Mean difference (final values): 0.404 · 80% CI 0.121 to 0.687P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • Placebo vs EOS+ Benralizumab, 20 mg · ANCOVA · p = 0.049 · Mean difference (final values): 0.462 · 80% CI 0.163 to 0.761P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • Placebo vs Benralizumab (100 mg) · ANCOVA · p = 0.168 · Mean difference (final values): 0.238 · 80% CI 0.017 to 0.459P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
SecondaryChange From Baseline in European Quality of Life - 5 Dimensions (EQ-5D) Health State Evaluation at Week 52

The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The health state valuation was the summary score of mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a 3 category scale (no problem, moderate problem, severe problems). Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in European Quality of Life - 5 Dimensions (EQ-5D) Health State Evaluation at Week 52
units on a scalePlaceboEOS+ Benralizumab, 2 mgEOS+ Benralizumab, 20 mgBenralizumab (100 mg)
Baseline (n=213,79,74,209)0.7629 ± 0.21530.7418 ± 0.23760.7877 ± 0.18780.7679 ± 0.1623
Change at Week 52 (n=148,58,53,161)0.0853 ± 0.20960.0822 ± 0.31370.1223 ± 0.21320.0824 ± 0.2179
Statistical analysis
  • Placebo vs EOS+ Benralizumab, 2 mg · ANCOVA · p = 0.510 · Mean difference (final values): -0.020 · 80% CI -0.058 to 0.019P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • Placebo vs EOS+ Benralizumab, 20 mg · ANCOVA · p = 0.113 · Mean difference (final values): 0.041 · 80% CI 0.008 to 0.074P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • Placebo vs Benralizumab (100 mg) · ANCOVA · p = 0.599 · Mean difference (final values): 0.011 · 80% CI -0.016 to 0.038P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
SecondaryChange From Baseline in EQ-5D Visual Analog Scale (VAS) at Week 52

The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The EQ-5D VAS was measured from 0 (worst imaginable health state) to 100 (best imaginable health state). Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in EQ-5D Visual Analog Scale (VAS) at Week 52
units on a scalePlaceboEOS+ Benralizumab, 2 mgEOS+ Benralizumab, 20 mgBenralizumab (100 mg)
Baseline (n=213,79,74,208)65.0798 ± 17.890365.4937 ± 18.506364.3378 ± 18.142764.6250 ± 19.7778
Change at Week 52 (n=148,58,53,161)12.8041 ± 19.103612.5517 ± 20.800815.4906 ± 21.729713.7391 ± 20.5139
Statistical analysis
  • Placebo vs EOS+ Benralizumab, 2 mg · ANCOVA · p = 0.871 · Mean difference (final values): -0.373 · 80% CI -3.333 to 2.586P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • Placebo vs EOS+ Benralizumab, 20 mg · ANCOVA · p = 0.227 · Mean difference (final values): 2.857 · 80% CI -0.175 to 5.889P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • Placebo vs Benralizumab (100 mg) · ANCOVA · p = 0.503 · Mean difference (final values): 1.139 · 80% CI -1.041 to 3.319P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
SecondaryChange From Baseline in Percentage of Nocturnal Awakening-Free Nights at Week 51-52

Percentage of nocturnal awakening-free nights were analyzed on a bi-weekly basis and compared to baseline scores. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

Time frame:
Baseline up to Week 51-52
Reported as:
Mean · percent nocturnal awakening-free nights
Change From Baseline in Percentage of Nocturnal Awakening-Free Nights at Week 51-52
percent nocturnal awakening-free nightsPlaceboEOS+ Benralizumab, 2 mgEOS+ Benralizumab, 20 mgBenralizumab (100 mg)
Baseline (n=204,72,74,210)52.05 ± 36.9645.07 ± 40.0451.57 ± 39.7250.92 ± 37.72
Change at Week 51-52 (n=111,36,39,111)19.7595 ± 39.138827.1749 ± 41.734229.6181 ± 38.431523.3054 ± 36.2761
Statistical analysis
  • Placebo vs EOS+ Benralizumab, 2 mg · ANCOVA · p = 0.550 · Mean difference (final values): 3.907 · 80% CI -4.483 to 12.297P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • Placebo vs EOS+ Benralizumab, 20 mg · ANCOVA · p = 0.215 · Mean difference (final values): 7.659 · 80% CI -0.262 to 15.579P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • Placebo vs Benralizumab (100 mg) · ANCOVA · p = 0.413 · Mean difference (final values): 3.540 · 80% CI -2.006 to 9.086P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
SecondaryChange From Baseline in Mean Fraction Exhaled Nitric Oxide (FeNO) at Week 52

Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

Time frame:
Baseline up to Week 52
Reported as:
Mean · parts per billion
Change From Baseline in Mean Fraction Exhaled Nitric Oxide (FeNO) at Week 52
parts per billionPlaceboEOS+ Benralizumab, 2 mgEOS+ Benralizumab, 20 mgBenralizumab (100 mg)
Baseline (n=222,81,81,222)26.88 ± 23.5739.52 ± 32.6740.79 ± 31.0326.68 ± 23.10
Change at Week 52 (n=148,57,56,157)1.2523 ± 16.0200-3.2222 ± 33.2543-6.1905 ± 30.11031.4384 ± 28.9090
Statistical analysis
  • Placebo vs EOS+ Benralizumab, 2 mg · ANCOVA · p = 0.896P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • Placebo vs EOS+ Benralizumab, 20 mg · ANCOVA · p = 0.944P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
  • Placebo vs Benralizumab (100 mg) · ANCOVA · p = 0.667P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.

Adverse events

Collected over From initiation of investigational product administration up to Week 92. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EOS POS Placebo—7/80 (8.8%)44/80 (55%)
EOS POS Benralizumab 2 mg—10/81 (12.3%)54/81 (66.7%)
EOS POS Benralizumab 20 mg—6/81 (7.4%)57/81 (70.4%)
EOS POS Benralizumab 100 mg—6/82 (7.3%)68/82 (82.9%)
EOS NEG Placebo—16/141 (11.3%)94/141 (66.7%)
EOS NEG Benralizumab 100 mg—18/141 (12.8%)93/141 (66%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventEOS POS PlaceboEOS POS Benralizumab 2 mgEOS POS Benralizumab 20 mgEOS POS Benralizumab 100 mgEOS NEG PlaceboEOS NEG Benralizumab 100 mg
AsthmaRespiratory, thoracic and mediastinal disorders2/802/810/812/828/1415/141
Myocardial ischaemiaCardiac disorders0/800/812/810/820/1410/141
Back painMusculoskeletal and connective tissue disorders0/802/810/810/820/1410/141
PneumoniaInfections and infestations0/801/810/811/821/1413/141
Abdominal herniaGastrointestinal disorders1/800/810/810/820/1410/141
Abdominal painGastrointestinal disorders1/800/810/811/820/1411/141
Fibrous histiocytomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/800/810/810/820/1410/141
SyncopeNervous system disorders1/800/810/810/820/1410/141
Asthmatic crisisRespiratory, thoracic and mediastinal disorders1/800/811/810/820/1410/141
Umbilical herniaGastrointestinal disorders1/800/810/810/820/1410/141
Most frequent other events
Showing 10 of 20
Most frequent other events
EventEOS POS PlaceboEOS POS Benralizumab 2 mgEOS POS Benralizumab 20 mgEOS POS Benralizumab 100 mgEOS NEG PlaceboEOS NEG Benralizumab 100 mg
AsthmaRespiratory, thoracic and mediastinal disorders30/8028/8124/8126/8242/14142/141
NasopharyngitisInfections and infestations8/8011/817/8113/825/14113/141
HeadacheNervous system disorders8/808/816/819/828/14113/141
BronchitisInfections and infestations3/808/816/813/8213/1419/141
PharyngitisInfections and infestations3/808/813/817/825/1416/141
Rhinitis allergicRespiratory, thoracic and mediastinal disorders3/803/818/816/824/1415/141
Injection site erythemaGeneral disorders0/802/812/818/820/14110/141
InfluenzaInfections and infestations4/803/817/816/8210/1416/141
Upper respiratory tractInfections and infestations4/807/817/815/8210/14111/141
Injection site painGeneral disorders0/806/814/812/826/1412/141

Baseline characteristics

The modified intent-to-treat (mITT) population included all randomized participants who received any dose of investigational product.

Age, Continuous
Age, Continuous(years)Eosinophilic Phenotype (EOS+) PlaceboEOS+ Benralizumab, 2 mgEOS+ Benralizumab, 20 mgEOS+ Benralizumab, 100 mgNon-eosinophil Phenotype (EOS-) PlaceboEOS- Benralizumab, 100 mgTotal
Mean45.6 ± 11.747.1 ± 12.846.6 ± 13.247.8 ± 12.950.0 ± 12.350.0 ± 11.548.3 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Eosinophilic Phenotype (EOS+) PlaceboEOS+ Benralizumab, 2 mgEOS+ Benralizumab, 20 mgEOS+ Benralizumab, 100 mgNon-eosinophil Phenotype (EOS-) PlaceboEOS- Benralizumab, 100 mgTotal
Female5358486010098417
Male272333224242189
08

Study locations

79 sites
  • Research Site
    Birmingham, Alabama, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Orange, California, United States
  • Research Site
    San Diego, California, United States
  • Research Site
    Stockton, California, United States
  • Research Site
    Colorado Springs, Colorado, United States
  • Research Site
    Denver, Colorado, United States
  • Research Site
    Waterbury, Connecticut, United States
  • Research Site
    Kissimmee, Florida, United States
  • Research Site
    Tampa, Florida, United States
  • Research Site
    Stockbridge, Georgia, United States
  • Research Site
    Normal, Illinois, United States
  • Research Site
    Baltimore, Maryland, United States
  • Research Site
    Rochester, Minnesota, United States
  • Research Site
    St Louis, Missouri, United States
  • Research Site
    St. Louis, Missouri, United States
  • Research Site
    Bellevue, Nebraska, United States
  • Research Site
    Summit, New Jersey, United States
  • Research Site
    Rochester, New York, United States
  • Research Site
    Winston-Salem, North Carolina, United States
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Blue Bell, Pennsylvania, United States
  • Research Site
    Pittsburgh, Pennsylvania, United States
  • Research Site
    Warwick, Rhode Island, United States
  • Research Site
    Boerne, Texas, United States
  • Research Site
    San Antonio, Texas, United States
  • Research Site
    Seattle, Washington, United States
  • Research Site
    Caba, Argentina
  • Research Site
    Ciudad de Buenos Aires, Argentina
  • Research Site
    Santa Fe, Argentina
  • Research Site
    Tucumán, Argentina
  • Research Site
    Curitiba, Brazil
  • Research Site
    Florianópolis, Brazil
  • Research Site
    Juiz de Fora, Brazil
  • Research Site
    Porto Alegre, Brazil
  • Research Site
    Rio de Janeiro, Brazil
  • Research Site
    Salvador, Brazil
  • Research Site
    Santo André, Brazil
  • Research Site
    Sao Paulo, Brazil
  • Research Site
    São Paulo, Brazil
  • Research Site
    Pleven, Bulgaria
  • Research Site
    Ruse, Bulgaria
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Troyan, Bulgaria
  • Research Site
    Brampton, Ontario, Canada
  • Research Site
    Toronto, Ontario, Canada
  • Research Site
    La Malbaie, Quebec, Canada
  • Research Site
    Quebec, Canada
  • Research Site
    Bogota, Colombia
  • Research Site
    Bogotá, Colombia
  • Research Site
    Guadalajara, Mexico
  • Research Site
    Mexico, Mexico
  • Research Site
    Monterrey, Mexico
  • Research Site
    Morelia, Mexico
  • Research Site
    Villahermosa, Mexico
  • Research Site
    Zapopan, Mexico
  • Research Site
    Lima, Peru
  • Research Site
    San Borja, Peru
  • Research Site
    San Isidro, Peru
  • Research Site
    Surco, Peru
  • Research Site
    Białystok, Poland
  • Research Site
    Bydgoszcz, Poland
  • Research Site
    Lublin, Poland
  • Research Site
    Ostrów Wielkopolski, Poland
  • Research Site
    Pila, Poland
  • Research Site
    Poznań, Poland
  • Research Site
    Tarnów, Poland
  • Research Site
    Warszawa, Poland
  • Research Site
    Łódź, Poland
  • Research Site
    Barnaul, Russian Federation
  • Research Site
    Chelyabinsk, Russian Federation
  • Research Site
    Ekaterinburg, Russian Federation
  • Research Site
    Kazan, Russian Federation
  • Research Site
    Moscow, Russian Federation
  • Research Site
    Novosibirsk, Russian Federation
  • Research Site
    Saint Petersburg, Russian Federation
  • Research Site
    Saint-Petersburg, Russian Federation
  • Research Site
    St-Petersburg, Russian Federation
09

References and documents

Publications

  • Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B, Khatry DB, van der Merwe R, Kolbeck R, Molfino NA, Raible DG. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014 Nov;2(11):879-890. doi: 10.1016/S2213-2600(14)70201-2. Epub 2014 Oct 8. PubMed 25306557 ↗
  • Sridhar S, Liu H, Pham TH, Damera G, Newbold P. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases. Respir Res. 2019 Jan 18;20(1):14. doi: 10.1186/s12931-018-0968-8. PubMed 30658649 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Mar 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2010
First posted
Nov 11, 2010
Start
Dec 2010
Primary completionActual
Mar 2013
CompletionActual
Aug 2013
Results first posted
Nov 17, 2016
Last update
Nov 17, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01238861
Lead sponsor
MedImmune LLC
Collaborators
MedImmune Ltd
Responsible party
Sponsor
First posted
Nov 11, 2010
Start date
Dec 2010
Primary completion
Mar 2013
Completion
Aug 2013
Results posted
Nov 17, 2016
Last update
Nov 17, 2016

Study contacts

Donald Raible, MD
study director · MedImmune LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion